Clinical Trial Update: PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin [Phase 1]

View source ↗

Summary

Phase 1 PK study of YH22189 fixed-dose combination compared with Telmisartan/Amlodipine and Rosuvastatin was terminated. The study targeted hypertension and hyp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Hypertension

Drugs mentioned

• Amlodipine (amlodipine)
• Rosuvastatin (rosuvastatin)
• Telmisartan (Telmisartan)
• YH22189 FDC (YH22189 fixed-dose combination)

Snippet

Sponsor: Yuhan Corporation | Conditions: Hypertension, Hyperlipidemia | Phase 1 | Status: TERMINATED